An analysis of genetic data from the UK Biobank and the Psychiatric Genomics Consortium has indicated that individuals with higher estimated levels of omega-3 fatty acids in their bodies are less likely to suffer from major depressive disorder. The strongest association with lower depression risk was found for eicosapentaenoic acid, a long-chain omega-3 fatty acid. These findings were published in the journal Translational Psychiatry.
Omega-3 fatty acids are a group of essential polyunsaturated fats crucial for maintaining overall health. The three main types are alpha-linolenic acid (ALA), which is found in plant oils like flaxseed and chia seeds, and eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), which are predominantly found in marine oils such as fish and algae.
These fatty acids are vital for brain function, reducing inflammation, and supporting heart health. Since the human body cannot efficiently synthesize omega-3 fatty acids, they must be obtained through diet or supplements. Studies have linked omega-3 fatty acids to numerous health benefits, including reducing the risk of chronic diseases such as heart disease and potentially alleviating symptoms of depression and anxiety.
While ALA can be converted into other types of omega-3 fatty acids, these processes tend to be variable and relatively inefficient due to competition for metabolic pathways with other fatty acids, most notably omega-6 fatty acids.
Study author Rebecca Carnegie and her colleagues aimed to explore the link between omega-3 fatty acids in the body and recurrent depression, also known as major depressive disorder with recurrent episodes. This mental health condition is characterized by multiple episodes of depression over time, each lasting at least two weeks. These episodes involve persistent feelings of sadness, loss of interest or pleasure in activities, changes in appetite or sleep, and difficulties in thinking or concentrating that significantly impair daily functioning.
The researchers conducted a Mendelian randomization study using data from two sources: the UK Biobank, which included 115,078 individuals, and the Psychiatric Genomics Consortium (PGC) genome-wide association studies (GWAS) of major depressive disorder, which included 430,775 individuals, and recurrent depression, which included 80,933 individuals.
They identified genetic variants associated with the metabolism, transport, and synthesis of omega-3 fatty acids in the body and used these variants to estimate the levels of omega-3 fatty acids. Although omega-3 fatty acids are primarily obtained through diet, the efficiency of their utilization and the levels present in the body can be influenced by specific genetic factors.
The study results showed that individuals with higher estimated genetic levels of omega-3 fatty acids had a somewhat lower risk of major depressive disorder. In contrast, genetically elevated levels of omega-6 fatty acids were not associated with an increased risk of major depressive disorder. A similar pattern was observed for recurrent depression: individuals with higher estimated genetic levels of omega-3 fatty acids were less likely to suffer from recurrent depression. The largest effects on these risk reductions were attributed to eicosapentaenoic acid.
“Our results provide evidence for a link between genetically predicted omega-3 fatty acids and MDD [major depressive disorder]. The effect appears strongest for EPA [eicosapentaenoic acid], remains robust to biologically correlated lipids, and is not explained by reverse causality [it is omega-3 fatty acids that affect depression, not depression that affects omega-3 fatty acid levels],” the study authors concluded.
While the study sheds light on the likely role of omega-3 fatty acids in depression, the observed effects were relatively small, indicating that the role of omega-3 fatty acids in the development of depression is likely minor. Additionally, the study’s focus on individuals of European ancestry may limit the generalizability of the findings to other populations. Furthermore, the exact levels of EPA and DHA were not directly measured in all cases, requiring the use of proxy data, which might introduce some inaccuracies. The potential for pleiotropy—where genetic variants influence multiple traits—also complicates the interpretation of causal relationships.
Future research could benefit from integrating genetic data with detailed dietary assessments to provide a more comprehensive understanding of how omega-3 fatty acids influence mental health. Further studies could also explore the differential effects of EPA and DHA on potential mediators, such as inflammation, to strengthen the rationale for high-dose EPA interventions. Given the relatively small effect sizes, future trials might consider targeting participants with suboptimal long-chain omega-3 fatty acid intake or high omega-6 to omega-3 ratios to yield greater benefits.
The paper, “Omega-3 fatty acids and major depression: a Mendelian randomization study,” was authored by R. Carnegie, M. C. Borges, H. J. Jones, J. Zheng, P. Haycock, J. Evans, and R. M. Martin.